Acquisition Target Recent acquisition by Ampersand Capital Partners in February 2026 signals a growth trajectory and potential integration opportunities for Purna’s development and manufacturing services, particularly for portfolio companies needing CMO/CDMO scale.

Digital Footprint Active online presence and modern tech stack including LinkedIn and recruitment platforms suggest readiness for outreach campaigns and collaboration with commercial teams to identify co-development or out-licensing opportunities.

Market Reach Global reputation as a preferred partner for top-10 multinationals and a track record of serving startups indicates a broad addressable market for contract development and manufacturing of semi-solid, powder, and liquid dosage forms across diverse clients.

R&D & Partnerships Commitment to R&D and an innovation network enables Purna to identify and license high-impact drug candidates or technologies, presenting opportunities for strategic partnerships, out-licensing deals, or collaborative development programs.

Financial Signals Revenue in the low tens of millions range with a recent private equity acquisition hint at potential capacity for ramping operations, upgraded facilities, or expanded service offerings that sales teams can position to prospective clients needing scalable manufacturing solutions.